AppLovin Earnings: Q4 Profit Soars After Revenue Beat

AppLovin earnings showed hefty margins and $3.95B free cash flow that funded $2.58B of buybacks, signaling buyback-driven flow for traders.

February 11, 2026·2 min read
View all news articles
Flat-vector server icon symbolizing AppLovin earnings margin strength and $2.58B in buybacks funding returns.

KEY TAKEAWAYS

  • Q4 revenue was $1.66 billion, a 66% year-over-year increase.
  • Full-year adjusted-EBITDA margin reached 82% for 2025.
  • 2025 free cash flow totaled $3.95 billion and funded $2.58 billion in repurchases.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

AppLovin Corporation said in its Feb. 11, 2026 earnings release that its fourth-quarter profit rose sharply, driven by sustained margin strength despite softer advertising demand. The company also issued guidance for the first quarter of 2026.

Q4 and Full-Year Results

AppLovin reported fourth-quarter 2025 revenue of $1.66 billion, a 66% increase from $999 million a year earlier. Net income reached $1.10 billion, representing a 66% net margin. Adjusted earnings per share were $3.24, about 12% above consensus estimates. Adjusted EBITDA, a proxy for operating profit, totaled $1.40 billion.

For the full year, revenue rose 70% to $5.48 billion, while net income more than doubled to $3.33 billion. Adjusted EBITDA increased 87% to $4.51 billion, producing an 82% adjusted-EBITDA margin for 2025.

Guidance and Capital Returns

The company forecasted first-quarter 2026 revenue between $1.745 billion and $1.775 billion, with adjusted EBITDA of $1.465 billion to $1.495 billion, implying an 84% margin, according to an 8-K filing. An earnings-call webcast followed the release.

AppLovin generated $3.95 billion in free cash flow and $3.97 billion in net cash from operating activities in 2025. It repurchased 6.4 million shares for $2.58 billion, ending the quarter with 338 million shares outstanding. The strong cash flow and elevated adjusted margins funded these multibillion-dollar buybacks, highlighting the company’s capacity for shareholder returns despite weaker advertising markets.

The results reflect a business model converting high adjusted margins into cash and capital returns. The guidance signals management expects margin resilience to continue into the new quarter, supporting ongoing financial flexibility.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

OpenAI Employee Arrested Over Hidden Recording Device

OpenAI Employee Arrested Over Hidden Recording Device

OpenAI employee arrested after a hidden device was discovered; company says models identified installer and found no data loss easing investor risk.

Cipher Digital Convertible Notes Proposal Sends Shares Lower

Cipher Digital Convertible Notes Proposal Sends Shares Lower

Cipher Digital convertible notes proposal would raise $850 million and include a concurrent exchange, raising dilution concerns and pressuring shares.

Character.AI Bankruptcy Draws Disney Interest

Character.AI Bankruptcy Draws Disney Interest

Character.AI bankruptcy starts a Section 363 sale with Disney as stalking-horse and $20 million bid, compressing the auction and shaping recoveries.

AST SpaceMobile Downgrade Sparks Concern

AST SpaceMobile Downgrade Sparks Concern

AST SpaceMobile downgrade after Piper Sandler cut its target, citing launch pace doubts and SpaceX competition, tightening trader positioning.

Six Flags Over Georgia Incident Prompts Ride Closures

Six Flags Over Georgia Incident Prompts Ride Closures

Six Flags Over Georgia incident triggered precautionary coaster closures and state reviews, raising near-term operational risk to attendance and shares.

Johnson & Johnson Q3 2026 Earnings Rise, MedTech Lags

Johnson & Johnson Q3 2026 Earnings Rise, MedTech Lags

Johnson & Johnson Q3 2026 earnings raised guidance to a $101.2 billion sales midpoint while MedTech weakness may force traders to reprice device risk.